Free Turing Pharmaceuticals: The Ethics of Drug Pricing Case Study Solution | Assignment Help

Harvard Case - Turing Pharmaceuticals: The Ethics of Drug Pricing

"Turing Pharmaceuticals: The Ethics of Drug Pricing" Harvard business case study is written by Shernaz Bodhanwala, Aakash Bothra. It deals with the challenges in the field of General Management. The case study is 9 page(s) long and it was first published on : Nov 8, 2017

At Fern Fort University, we recommend that Turing Pharmaceuticals implement a comprehensive strategy that prioritizes ethical drug pricing practices while balancing the need for profitability and innovation. This strategy should involve a multi-pronged approach focused on transparent pricing, stakeholder engagement, and a commitment to responsible business practices.

2. Background

The case study focuses on Turing Pharmaceuticals, a company founded by Martin Shkreli, who acquired the rights to Daraprim, a drug used to treat toxoplasmosis, a parasitic infection that can be life-threatening for individuals with weakened immune systems. Shkreli infamously increased the price of Daraprim by 5,000%, leading to widespread public outcry and accusations of price gouging. This decision triggered a national debate on the ethics of drug pricing and the role of pharmaceutical companies in providing essential medications.

The main protagonists of the case study are Martin Shkreli, the controversial CEO of Turing Pharmaceuticals, and the patients and healthcare providers who rely on Daraprim for treatment. The case study also highlights the role of government agencies, the media, and the public in shaping the ethical landscape of drug pricing.

3. Analysis of the Case Study

The case study can be analyzed through the lens of several frameworks, including:

  • Business Ethics: Turing Pharmaceuticals' decision to increase Daraprim's price by 5,000% raises significant ethical concerns. The company's actions were perceived as prioritizing profit over patient welfare, leading to accusations of price gouging and exploitation.
  • Stakeholder Management: The case study highlights the importance of considering the interests of all stakeholders, including patients, healthcare providers, investors, and the public. Turing Pharmaceuticals failed to adequately address the concerns of these stakeholders, leading to a backlash that damaged the company's reputation.
  • Corporate Social Responsibility: The case study underscores the importance of corporate social responsibility in the pharmaceutical industry. Turing Pharmaceuticals' actions were seen as a violation of ethical business practices and a disregard for the social impact of their pricing decisions.
  • Competitive Strategy: The case study raises questions about the sustainability of a business model based on price gouging. Turing Pharmaceuticals' actions may have generated short-term profits but ultimately damaged the company's long-term prospects by alienating key stakeholders.

4. Recommendations

To address the ethical concerns surrounding Turing Pharmaceuticals' pricing practices, we recommend the following:

  • Implement Transparent Pricing Policies: Turing Pharmaceuticals should adopt a transparent pricing policy that clearly explains the rationale behind its pricing decisions. This policy should be communicated to all stakeholders, including patients, healthcare providers, and the public.
  • Engage with Stakeholders: Turing Pharmaceuticals should actively engage with stakeholders to understand their concerns and perspectives on drug pricing. This engagement should be ongoing and involve open dialogue and collaboration.
  • Develop a Patient Assistance Program: Turing Pharmaceuticals should establish a patient assistance program to ensure that patients with financial hardship can access Daraprim. This program should be designed to provide affordable access to the drug without compromising the company's financial viability.
  • Invest in Research and Development: Turing Pharmaceuticals should invest in research and development to develop innovative treatments for toxoplasmosis and other neglected diseases. This commitment to innovation will help the company create value for patients and stakeholders.
  • Adopt a Code of Ethics: Turing Pharmaceuticals should develop and implement a code of ethics that outlines its commitment to ethical business practices. This code should be communicated to all employees and serve as a guiding principle for decision-making.

5. Basis of Recommendations

These recommendations are based on the following considerations:

  • Core Competencies and Consistency with Mission: The recommendations align with the core competencies of pharmaceutical companies, which include developing and manufacturing innovative drugs, ensuring patient access to essential medications, and operating ethically.
  • External Customers and Internal Clients: The recommendations address the needs of external customers (patients and healthcare providers) and internal clients (employees). By implementing transparent pricing policies, engaging with stakeholders, and developing a patient assistance program, Turing Pharmaceuticals can build trust and goodwill with its customers and employees.
  • Competitors: The recommendations consider the competitive landscape of the pharmaceutical industry. By focusing on innovation, ethical pricing, and patient access, Turing Pharmaceuticals can differentiate itself from competitors and establish a strong reputation in the market.
  • Attractiveness ' Quantitative Measures: The recommendations are attractive from a financial perspective. By implementing transparent pricing policies, engaging with stakeholders, and developing a patient assistance program, Turing Pharmaceuticals can potentially mitigate the risk of regulatory scrutiny and public backlash, leading to long-term financial stability.

6. Conclusion

Turing Pharmaceuticals' decision to increase Daraprim's price by 5,000% was a significant ethical lapse that damaged the company's reputation and sparked a national debate on drug pricing. The company must prioritize ethical business practices, transparent pricing, and stakeholder engagement to restore its credibility and ensure long-term sustainability. By implementing the recommendations outlined above, Turing Pharmaceuticals can create a more ethical and sustainable business model that benefits patients, healthcare providers, and the company itself.

7. Discussion

Other alternatives to the recommendations include:

  • Maintaining the current pricing strategy: This option would likely result in continued public backlash and regulatory scrutiny, potentially leading to legal challenges and financial instability.
  • Selling the rights to Daraprim: This option would remove Turing Pharmaceuticals from the center of the controversy but could result in a loss of revenue and potentially lead to a similar pricing strategy by the new owner.

The recommendations outlined in this case study solution are based on the assumption that Turing Pharmaceuticals is committed to ethical business practices and is willing to make the necessary changes to restore its reputation. However, there is a risk that the company may resist these recommendations, leading to further ethical dilemmas and financial instability.

8. Next Steps

To implement the recommendations, Turing Pharmaceuticals should take the following steps:

  • Form a task force: The company should form a task force to develop and implement the recommendations, including representatives from various departments, such as finance, marketing, and legal.
  • Communicate with stakeholders: The task force should communicate the recommendations to all stakeholders, including patients, healthcare providers, investors, and the public.
  • Develop a timeline: The task force should develop a timeline for implementing the recommendations, including specific milestones and deadlines.
  • Monitor progress: The task force should monitor the progress of implementation and make adjustments as needed.

By taking these steps, Turing Pharmaceuticals can begin to address the ethical concerns surrounding its pricing practices and build a more sustainable and ethical business model.

Hire an expert to write custom solution for HBR General Management case study - Turing Pharmaceuticals: The Ethics of Drug Pricing

Case Description

In 2015 there was a public outcry over the price increase in Daraprim (pyrimethamine) by Turing Pharmaceuticals AG (Turing). Daraprim was a drug that was widely used by a small population of U.S. patients to treat toxoplasmosis. Soon after Turing acquired its commercialization rights in August 2015, the company increased the list price of the drug by over 5,000 per cent. The increase led to consumer protests in the United States, and the media vehemently condemned Turing's action of raising the price for the decades-old drug that had gone off-patent in 1970. Later, the U.S. Congress stepped in, demanding that Turing's officials clarify how they could justify the high price of Daraprim. How should Turing respond to the public outcry? Should Turing stand by the increased price for Daraprim? How could it handle the outcry from the patient groups that needed Daraprim?

🎓 Struggling with term papers, essays, or Harvard case studies? Look no further! Fern Fort University offers top-quality, custom-written solutions tailored to your needs. Boost your grades and save time with expertly crafted content. Order now and experience academic excellence! 🌟📚 #MBA #HarvardCaseStudies #CustomEssays #AcademicSuccess #StudySmart Write my custom case study solution for Harvard HBR case - Turing Pharmaceuticals: The Ethics of Drug Pricing

Hire an expert to write custom solution for HBR General Management case study - Turing Pharmaceuticals: The Ethics of Drug Pricing

Turing Pharmaceuticals: The Ethics of Drug Pricing FAQ

What are the qualifications of the writers handling the "Turing Pharmaceuticals: The Ethics of Drug Pricing" case study?

Our writers hold advanced degrees in their respective fields, including MBAs and PhDs from top universities. They have extensive experience in writing and analyzing complex case studies such as " Turing Pharmaceuticals: The Ethics of Drug Pricing ", ensuring high-quality, academically rigorous solutions.

How do you ensure confidentiality and security in handling client information?

We prioritize confidentiality by using secure data encryption, access controls, and strict privacy policies. Apart from an email, we don't collect any information from the client. So there is almost zero risk of breach at our end. Our financial transactions are done by Paypal on their website so all your information is very secure.

What is Fern Fort Univeristy's process for quality control and proofreading in case study solutions?

The Turing Pharmaceuticals: The Ethics of Drug Pricing case study solution undergoes a rigorous quality control process, including multiple rounds of proofreading and editing by experts. We ensure that the content is accurate, well-structured, and free from errors before delivery.

Where can I find free case studies solution for Harvard HBR Strategy Case Studies?

At Fern Fort University provides free case studies solutions for a variety of Harvard HBR case studies. The free solutions are written to build "Wikipedia of case studies on internet". Custom solution services are written based on specific requirements. If free solution helps you with your task then feel free to donate a cup of coffee.

I’m looking for Harvard Business Case Studies Solution for Turing Pharmaceuticals: The Ethics of Drug Pricing. Where can I get it?

You can find the case study solution of the HBR case study "Turing Pharmaceuticals: The Ethics of Drug Pricing" at Fern Fort University.

Can I Buy Case Study Solution for Turing Pharmaceuticals: The Ethics of Drug Pricing & Seek Case Study Help at Fern Fort University?

Yes, you can order your custom case study solution for the Harvard business case - "Turing Pharmaceuticals: The Ethics of Drug Pricing" at Fern Fort University. You can get a comprehensive solution tailored to your requirements.

Can I hire someone only to analyze my Turing Pharmaceuticals: The Ethics of Drug Pricing solution? I have written it, and I want an expert to go through it.

🎓 Struggling with term papers, essays, or Harvard case studies? Look no further! Fern Fort University offers top-quality, custom-written solutions tailored to your needs. Boost your grades and save time with expertly crafted content. Order now and experience academic excellence! 🌟📚 #MBA #HarvardCaseStudies #CustomEssays #AcademicSuccess #StudySmart Pay an expert to write my HBR study solution for the case study - Turing Pharmaceuticals: The Ethics of Drug Pricing

Where can I find a case analysis for Harvard Business School or HBR Cases?

You can find the case study solution of the HBR case study "Turing Pharmaceuticals: The Ethics of Drug Pricing" at Fern Fort University.

Which are some of the all-time best Harvard Review Case Studies?

Some of our all time favorite case studies are -

Can I Pay Someone To Solve My Case Study - "Turing Pharmaceuticals: The Ethics of Drug Pricing"?

Yes, you can pay experts at Fern Fort University to write a custom case study solution that meets all your professional and academic needs.

Do I have to upload case material for the case study Turing Pharmaceuticals: The Ethics of Drug Pricing to buy a custom case study solution?

We recommend to upload your case study because Harvard HBR case studies are updated regularly. So for custom solutions it helps to refer to the same document. The uploading of specific case materials for Turing Pharmaceuticals: The Ethics of Drug Pricing ensures that the custom solution is aligned precisely with your needs. This helps our experts to deliver the most accurate, latest, and relevant solution.

What is a Case Research Method? How can it be applied to the Turing Pharmaceuticals: The Ethics of Drug Pricing case study?

The Case Research Method involves in-depth analysis of a situation, identifying key issues, and proposing strategic solutions. For "Turing Pharmaceuticals: The Ethics of Drug Pricing" case study, this method would be applied by examining the case’s context, challenges, and opportunities to provide a robust solution that aligns with academic rigor.

"I’m Seeking Help with Case Studies,” How can Fern Fort University help me with my case study assignments?

Fern Fort University offers comprehensive case study solutions, including writing, analysis, and consulting services. Whether you need help with strategy formulation, problem-solving, or academic compliance, their experts are equipped to assist with your assignments.

Achieve academic excellence with Fern Fort University! 🌟 We offer custom essays, term papers, and Harvard HBR business case studies solutions crafted by top-tier experts. Experience tailored solutions, uncompromised quality, and timely delivery. Elevate your academic performance with our trusted and confidential services. Visit Fern Fort University today! #AcademicSuccess #CustomEssays #MBA #CaseStudies

How do you handle tight deadlines for case study solutions?

We are adept at managing tight deadlines by allocating sufficient resources and prioritizing urgent projects. Our team works efficiently without compromising quality, ensuring that even last-minute requests are delivered on time

What if I need revisions or edits after receiving the case study solution?

We offer free revisions to ensure complete client satisfaction. If any adjustments are needed, our team will work closely with you to refine the solution until it meets your expectations.

How do you ensure that the case study solution is plagiarism-free?

All our case study solutions are crafted from scratch and thoroughly checked using advanced plagiarism detection software. We guarantee 100% originality in every solution delivered

How do you handle references and citations in the case study solutions?

We follow strict academic standards for references and citations, ensuring that all sources are properly credited according to the required citation style (APA, MLA, Chicago, etc.).

Hire an expert to write custom solution for HBR General Management case study - Turing Pharmaceuticals: The Ethics of Drug Pricing




Referrences & Bibliography for SWOT Analysis | SWOT Matrix | Strategic Management

1. Andrews, K. R. (1980). The concept of corporate strategy. Harvard Business Review, 61(3), 139-148.

2. Ansoff, H. I. (1957). Strategies for diversification. Harvard Business Review, 35(5), 113-124.

3. Brandenburger, A. M., & Nalebuff, B. J. (1995). The right game: Use game theory to shape strategy. Harvard Business Review, 73(4), 57-71.

4. Christensen, C. M., & Raynor, M. E. (2003). Why hard-nosed executives should care about management theory. Harvard Business Review, 81(9), 66-74.

5. Christensen, C. M., & Raynor, M. E. (2003). The innovator's solution: Creating and sustaining successful growth. Harvard Business Review Press.

6. D'Aveni, R. A. (1994). Hypercompetition: Managing the dynamics of strategic maneuvering. Harvard Business Review Press.

7. Ghemawat, P. (1991). Commitment: The dynamic of strategy. Harvard Business Review, 69(2), 78-91.

8. Ghemawat, P. (2002). Competition and business strategy in historical perspective. Business History Review, 76(1), 37-74.

9. Hamel, G., & Prahalad, C. K. (1990). The core competence of the corporation. Harvard Business Review, 68(3), 79-91.

10. Kaplan, R. S., & Norton, D. P. (1992). The balanced scorecard--measures that drive performance. Harvard Business Review, 70(1), 71-79.

11. Kim, W. C., & Mauborgne, R. (2004). Blue ocean strategy. Harvard Business Review, 82(10), 76-84.

12. Kotter, J. P. (1995). Leading change: Why transformation efforts fail. Harvard Business Review, 73(2), 59-67.

13. Mintzberg, H., Ahlstrand, B., & Lampel, J. (2008). Strategy safari: A guided tour through the wilds of strategic management. Harvard Business Press.

14. Porter, M. E. (1979). How competitive forces shape strategy. Harvard Business Review, 57(2), 137-145.

15. Porter, M. E. (1980). Competitive strategy: Techniques for analyzing industries and competitors. Simon and Schuster.

16. Porter, M. E. (1985). Competitive advantage: Creating and sustaining superior performance. Free Press.

17. Prahalad, C. K., & Hamel, G. (1990). The core competence of the corporation. Harvard Business Review, 68(3), 79-91.

18. Rumelt, R. P. (1979). Evaluation of strategy: Theory and models. Strategic Management Journal, 1(1), 107-126.

19. Rumelt, R. P. (1984). Towards a strategic theory of the firm. Competitive Strategic Management, 556-570.

20. Teece, D. J., Pisano, G., & Shuen, A. (1997). Dynamic capabilities and strategic management. Strategic Management Journal, 18(7), 509-533.